Clinical trials: Lymphatic Filariasis
Lymphatic Filariases, Onchocerciasis
Prevalence of LF Infection in Districts Not Included in LF Control Activities
Lymphatic filariasis is a neglected tropical disease earmarked for elimination as a public health problem by the year 2020. Since the year 2000, the Global Program for the Elimination of LF has together with endemic countries…
- Trial name
- NCT03131401
- Testing
- Diagnosis of lymphatic filariasis, Diagnosis of lymphatic Filariasis and onchocerciasis, DEC Patch
- Where
- Ghana
- Volunteers
- 3,736 people
- Sponsor
- Noguchi Memorial Institute for Medical Research
Trachoma, Lymphatic Filariasis
Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis
Trachoma and lymphatic filariasis (LF) are two 'Neglected Tropical Diseases' (NTDs), infectious diseases that affect millions of poor people in countries in the developing world.
- Trial name
- AZIVAL2 (NCT01903057)
- Testing
- azithromycin, ivermectin, albendazole
- Where
- Mozambique
- Volunteers
- healthy volunteers welcome
- Sponsor
- Emory University
Onchocerciasis, Epilepsy
Impact of a Bi-annual CDTI on the Incidence of Epilepsy in an Onchocerciasis-endemic Area
Onchocerciasis is a neglected tropical disease associated with epilepsy, particularly in areas of high Onchocerciasis volvulus transmission.
- Trial name
- OAETanzania (NCT05749653)
- Testing
- Bi-annual CDTI
- Where
- Tanzania
- Volunteers
- 6,500 people, healthy volunteers welcome
- Sponsor
- Universiteit Antwerpen
Skin and Connective Tissue Diseases, Neglected Tropical Diseases
Early Detection and AI-Based Management of Skin-Related Neglected Tropical Diseases in Sub-Saharan Africa by Frontline Health Workers
Skin-related Neglected Tropical Diseases (Skin NTDs) affect about 1.8 billion people worldwide, particularly in poor and rural communities where healthcare access is limited.
- Conditions
- Skin and Connective Tissue Diseases, Neglected Tropical Diseases, Leprosy, Buruli Ulcer
- Trial name
- SkincAIr (NCT07506967)
- Testing
- A mobile app with AI functionality for diagnosing skin-related NTDs
- Where
- 5 sites in Democratic Republic of the Congo, Ethiopia and 3 more
- Volunteers
- 2,420 people
- Sponsor
- Kenya Medical Research Institute
Lymphatic Filariasis
Effect of Albendazole Dose on Clearance of Filarial Worms
This study, conducted in Mali, West Africa, will determine whether a new treatment regimen for lymphatic filariasis can eliminate the disease more quickly than the standard regimen.
- Trial name
- NCT00339417
- Testing
- Albendazole, Ivermectin
- Where
- Mali
- Volunteers
- 1,000 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Mansonella Perstans Infection, Mp Microfilaremia
Doxycycline to Treat Mansonella Perstans Infection in Patients With and Without Lymphatic Filariasis
This study will examine: 1) the safety and effectiveness of the drug doxycycline in reducing the number of Mansonella perstans (Mp) worms in the blood of infected patients, and 2) the effects of doxycycline followed by…
- Trial name
- NCT00340691
- Testing
- Doxycycline
- Where
- United States
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lymphatic Filariasis, Helminth Infection
Twice Yearly Treatment for the Control of LF
The Global Program for the Elimination of Lymphatic Filariasis (GPELF) has been in operation sing the year 2000, with the aim of eliminating the disease by the year 2020, following 5-6 rounds of effective annual Mass Drug…
- Trial name
- NCT03036059
- Testing
- 400 μg/kg Ivermectin + 400 mg Albendazole
- Where
- Ghana
- Volunteers
- 1,462 people, healthy volunteers welcome
- Sponsor
- Noguchi Memorial Institute for Medical Research
Malaria, Filariasis
Medical Implications of Coinfection With Malaria and Filariasis Parasites
This study will examine the clinical, immunological and epidemiological effects of concurrent infections with P. falciparum and W. bancrofti or M.
- Trial name
- NCT00471666
- Where
- Mali
- Volunteers
- 1,039 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lymphatic Filariases
Prevalence Studies After Triple Drug Therapy for Lymphatic Filariasis
This study will assess the impact of 2-drug (DA) or 3-drug (IDA) regimens on lymphatic filariasis infection parameters in communities.
- Trial name
- NCT03352206
- Testing
- 2 drug dose - DA, 3 drug dose - IDA
- Where
- 5 sites in Fiji, Haiti and 3 more
- Volunteers
- 20,092 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Schistosomiasis
Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in People With Schistosomiasis
Background: Schistosomiasis is a chronic infection. It is caused by parasitic worms called Schistosoma haematobium (Sh) that are spread by snails that live in rivers. It can lead to liver problems or bladder cancer.
- Trial name
- NCT02734186
- Testing
- Praziquantel
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lymphatic Filariasis
Research for Elimination of Lymphatic Filariasis (ICIDR)
The purpose of this study is to check blood samples for lymphatic filariasis to determine whether the recent Program to Eliminate Lymphatic Filariasis was successful in controlling lymphatic filariasis in areas of Egypt.
- Trial name
- NCT00406627
- Where
- Egypt
- Volunteers
- 117,500 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Onchocerciasis
A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years
The primary purpose of this study is to determine a dose of moxidectin for children 4 to 11 years that is equivalent to an 8 mg dose administered for treatment of onchocerciasis in people 12 years and over.
- Trial name
- NCT03962062
- Testing
- Moxidectin
- Where
- Ghana
- Volunteers
- 36 people
- Sponsor
- Medicines Development for Global Health
Onchocerciasis
Ocular Changes After Ivermectin - (DOLF IVM/Oncho)
The DOLF Ocular Changes after Ivermectin study will investigate the kinetics of O. volvulus microfilaria (Mf) in the eye following treatment with ivermectin.
- Trial name
- NCT03517462
- Testing
- Ivermectin 3Mg Tab
- Where
- Ghana
- Volunteers
- 231 people
- Sponsor
- Washington University School of Medicine
Lymphedema, Cellulitis
Evaluation of Antibacterial Soap for Treatment of Lymphedema in a Filariasis-Endemic Area
Introduction. Lymphatic filariasis is a devastating mosquito-transmitted parasitic disease that causes lymphedema or elephantiasis of the leg in 15 million persons, the majority of whom are women.
- Trial name
- NCT00139100
- Testing
- antimicrobial agent in soap
- Where
- Haiti
- Volunteers
- 200 people
- Sponsor
- Centers for Disease Control and Prevention
Leprosy, Buruli Ulcer
Integrated Mapping of Skin-presenting Neglected Tropical Diseases in Liberia
Appropriate targeting of interventions for neglected tropical diseases (NTDs) that require innovative and intensified disease management (IDM) requires accurate data on the distribution of these diseases within endemic countries.
- Conditions
- Leprosy, Buruli Ulcer, Yaws, Lymphatic Filariases
- Trial name
- NCT03683745
- Where
- Liberia
- Volunteers
- 56,285 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Lymphatic Filariasis, Onchocerciasis
Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast)
Approximately 4,000 people will participate per year. The study population will include females and males over 5 years of age who live in filariasis and onchocerciasis endemic areas.
- Conditions
- Lymphatic Filariasis, Onchocerciasis, Soil Transmitted Helminth (STH) Infections
- Trial name
- NCT02032043
- Testing
- Annual versus Semiannual Albendazole plus Ivermectin MDA
- Where
- Côte d’Ivoire
- Volunteers
- 14,457 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Filariasis
Exhaled NO Testing in Filariasis
This study is looking at the difference in exhaled nitric oxide levels in patients with and without laboratory evidence of filariasis.
- Trial name
- NCT01628497
- Where
- Guyana
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Filariasis, Helminthiasis
Host Response to Infection and Treatment in Filarial Diseases
This study will evaluate and treat patients with filarial infections to explore in depth the immunology of the disease, including susceptibility to infection, disease development, and response to treatment.
- Conditions
- Filariasis, Helminthiasis, Parasitic Infection, Mansonelliasis
- Trial name
- NCT00001230
- Testing
- Diethylcarbamazine
- Where
- United States
- Volunteers
- 425 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Onchocerciasis
Safety and Efficacy of IDA for Onchocerciasis
This DOLF study will investigate the safety and effectiveness of IDA treatment in persons with onchocerciasis when it is administered after pre-treatment with ivermectin to clear or greatly reduce microfilariae from the skin and…
- Trial name
- DOLF IDA/Oncho (NCT04188301)
- Testing
- IVM w/ ALB, Single dose of IDA, Three daily doses of IDA
- Where
- Ghana
- Volunteers
- 154 people
- Sponsor
- Washington University School of Medicine
Lymphatic Filariasis Elimination by Mass Drug Administration, Monitoring and Evaluation of Mass Drug Administration for Lymphatic Filariasis
East New Britain Province Monitoring & Evaluation
While tremendous progress towards elimination of lymphatic filariasis (LF) has been made in the 20 years since the 1997 Fiftieth World Health Assembly, it is unlikely the goal of eliminating LF as a public health problem by 2020…
- Conditions
- Lymphatic Filariasis Elimination by Mass Drug Administration, Monitoring and Evaluation of Mass Drug Administration for Lymphatic Filariasis, Acceptability of Mass Drug Administration for Lymphatic Filariasis
- Trial name
- ENBP M&E (NCT04124250)
- Testing
- Observational
- Where
- Papua New Guinea
- Volunteers
- 12,930 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center